Tumor-related factors alone, such as programmed death-ligand 1 (PD-L1) expression, tumor mutational burden, tumor-infiltrating lymphocytes, and high microsatellite instability, do not completely explain the existing differences in immunotherapy efficacy [17]. This evidence concerns the gene CD274 and neoplasm.